ProQR Form4 Filing Shows CEO Daniel De Boer Buys 200,000 Shares At An Average Price Of $1.77; Increasing Direct Holdings to 500,000 Shares
ProQR Therapeutics Files Prospectus For Offering 3.03M Ordinary Shares On Behalf Of Selling Shareholder
ProQR Therapeutics: Human NTCP Data Strengthens The Axiomer Thesis
Evercore ISI Group Maintains Outperform on ProQR Therapeutics, Raises Price Target to $6
Chardan Capital Maintains Buy on ProQR Therapeutics, Lowers Price Target to $3
ProQR Therapeutics Announces Data From Its Ongoing Phase 1 Clinical Study Of AX-0810 Investigational Axiomer RNA Editing Oligonucleotide; Sees Target Engagement On All Key Biomarkers
ProQR Therapeutics N.V. (PRQR) Presents at 29th ASGCT Annual Meeting 2026 - Slideshow
ProQR Therapeutics N.V. (PRQR) Presents at TIDES USA 2026 - Slideshow
ProQR Therapeutics N.V. (NASDAQ:PRQR) Analysts Just Slashed This Year's Revenue Estimates By 22%
ProQR Announces First Quarter 2026 Operating and Financial Results
ProQR Therapeutics Q1 EPS $(0.15), Inline, Sales $2.381M Miss $5.530M Estimate
ProQR Announces Multiple Upcoming Scientific Conference Presentations Highlighting the Breadth of its Axiomer™ RNA Editing Platform
ProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026
ProQR Announces Nomination of Dr. Lykke Hinsch Gylvin to its Board of Directors
ProQR Therapeutics: Waiting On Proof As AX-0810 Data Approaches
ProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst Event
ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst Call Transcript
ProQR Therapeutics Unveils New RNA Editing Programs; AX-0810 Phase 1 Target Data Due This Quarter
ProQR Therapeutics Announces Key Updates During Virtual Event; Emphasizes Expansion Of Pipeline With Two New Programs And Leading RNA Editing Program On Track For Target Engagement Data
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.